Update cardio-oncology : Immune checkpoint inhibitor therapy
© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Cardiovascular diseases and cancer are the most common causes of death in Germany. Cancer treatment can lead to significant cardiovascular side effects and thus form a link between the two disease groups. The focus of cardio-oncology is on the best possible prevention, diagnostics and treatment of cardiovascular complications caused by cancer treatment. It is crucial for cardio-oncology to adapt to the continuous development of new forms of oncological treatment with previously unknown cardiovascular side effects. One such new form of treatment is immune checkpoint inhibitor (ICI) therapy, which is regarded as the most important oncological milestone of the last decade due to its excellent oncological efficacy; however, the growing use has revealed a high risk of diverse cardiovascular side effects with high morbidity and mortality, so that cardio-oncological care of affected patients is of particular importance. This review summarizes the current scientific and clinical state of the pathophysiology, incidence, diagnosis and treatment of cardiovascular side effects of ICI therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Herz - 49(2024), 1 vom: 28. Feb., Seite 81-90 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Update Kardioonkologie : Immuncheckpoint-Inhibitor-Therapie |
|---|
| Beteiligte Personen: |
Michel, Lars [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer treatment |
|---|
| Anmerkungen: |
Date Completed 02.02.2024 Date Revised 28.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00059-023-05228-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366659065 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366659065 | ||
| 003 | DE-627 | ||
| 005 | 20240229234705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00059-023-05228-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM366659065 | ||
| 035 | |a (NLM)38175285 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Michel, Lars |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Update cardio-oncology |b Immune checkpoint inhibitor therapy |
| 246 | 3 | 3 | |a Update Kardioonkologie : Immuncheckpoint-Inhibitor-Therapie |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2024 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Cardiovascular diseases and cancer are the most common causes of death in Germany. Cancer treatment can lead to significant cardiovascular side effects and thus form a link between the two disease groups. The focus of cardio-oncology is on the best possible prevention, diagnostics and treatment of cardiovascular complications caused by cancer treatment. It is crucial for cardio-oncology to adapt to the continuous development of new forms of oncological treatment with previously unknown cardiovascular side effects. One such new form of treatment is immune checkpoint inhibitor (ICI) therapy, which is regarded as the most important oncological milestone of the last decade due to its excellent oncological efficacy; however, the growing use has revealed a high risk of diverse cardiovascular side effects with high morbidity and mortality, so that cardio-oncological care of affected patients is of particular importance. This review summarizes the current scientific and clinical state of the pathophysiology, incidence, diagnosis and treatment of cardiovascular side effects of ICI therapy | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer treatment | |
| 650 | 4 | |a Cardiotoxicity | |
| 650 | 4 | |a Cardiovascular diseases | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Side effects | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Rassaf, Tienush |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Herz |d 1993 |g 49(2024), 1 vom: 28. Feb., Seite 81-90 |w (DE-627)NLM000324086 |x 1615-6692 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2024 |g number:1 |g day:28 |g month:02 |g pages:81-90 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00059-023-05228-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2024 |e 1 |b 28 |c 02 |h 81-90 | ||